Literature DB >> 11149130

Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension.

J T Flynn1, D A Pasko.   

Abstract

The calcium channel blockers (CCBs) are a diverse group of antihypertensive medications with variable pharmacokinetics and clinical effects. Although CCBs have been widely applied to the treatment of hypertensive children, data regarding the pharmacokinetics, efficacy and safety of these agents in children are extremely limited. In this review we briefly summarize the mechanism of action of CCBs and then summarize pertinent pharmacokinetic information on each of the CCBs commonly used in children, including amlodipine, diltiazem, felodipine, isradipine, intravenous nicardipine, nifedipine and verapamil. Clinically important drug interactions and adverse effects are discussed, as well as the potential role of CCBs in renal protection. Available pediatric efficacy and safety data are summarized, and recommendations made regarding the rational use of CCBs in the management of pediatric hypertension.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11149130     DOI: 10.1007/s004670000480

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  29 in total

1.  Hypertensive emergencies in children.

Authors:  Pankaj Hari; Aditi Sinha
Journal:  Indian J Pediatr       Date:  2011-01-27       Impact factor: 1.967

2.  Cyclosporin enhances the tendency towards oedema and flushing noted on dihydropyridine calcium channel blockers.

Authors:  R O von Vigier; E Fossali; A Edefonti; B Vogt; M G Bianchetti
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

Review 3.  Intravenous nicardipine: its use in the short-term treatment of hypertension and various other indications.

Authors:  Monique P Curran; Dean M Robinson; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Drug treatment of hypertensive crisis in children.

Authors:  Christopher A Thomas
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

Review 5.  Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation.

Authors:  Kevin Watt; Jennifer S Li; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  J Cardiovasc Pharmacol       Date:  2011-08       Impact factor: 3.105

Review 6.  Therapy of acute hypertension in hospitalized children and adolescents.

Authors:  Tennille N Webb; Ibrahim F Shatat; Yosuke Miyashita
Journal:  Curr Hypertens Rep       Date:  2014-04       Impact factor: 5.369

7.  Randomized, double-blind, controlled study of losartan in children with proteinuria.

Authors:  Nicholas J A Webb; Chun Lam; Tom Loeys; Shahnaz Shahinfar; Juergen Strehlau; Thomas G Wells; Emanuela Santoro; Denise Manas; Gilbert W Gleim
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-14       Impact factor: 8.237

8.  Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises.

Authors:  Karen J Loechner; James T McLaughlin; Ali S Calikoglu
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-24

Review 9.  Pharmacologic Management of Pediatric Hypertension.

Authors:  Jason Misurac; Kristen R Nichols; Amy C Wilson
Journal:  Paediatr Drugs       Date:  2016-02       Impact factor: 3.022

10.  In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models.

Authors:  Ying Sun; Benjamin Liou; Brian Quinn; Huimin Ran; You-Hai Xu; Gregory A Grabowski
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.